Truist Securities Maintains Buy on Immunogen, Raises Price Target to $18
Portfolio Pulse from Benzinga Newsdesk
Truist Securities analyst Asthika Goonewardene maintains a Buy rating on Immunogen (NASDAQ:IMGN) and raises the price target from $15 to $18.
June 06, 2023 | 1:06 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Truist Securities maintains a Buy rating on Immunogen and raises the price target from $15 to $18.
The news of Truist Securities maintaining a Buy rating on Immunogen and raising the price target from $15 to $18 indicates a positive outlook for the company's stock. This could lead to an increase in investor confidence and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100